Name: Michael Iskra
New title: CEO, Cleveland Diagnostics
Cleveland Diagnostics said this week that Michael Iskra is joining the company as its new CEO to accelerate commercial expansion of the IsoPSA prostate cancer assay.
The company obtained Food and Drug Administration premarket approval for the in vitro diagnostic kit in December. The test analyzes the structure of protein biomarkers in the blood for prostate cancer signals, to aid in determining whether a biopsy is needed.
The FDA approval allows the company to supply the assay as a kit to clinical laboratories nationwide, significantly expanding access to the test.
Iskra brings to the job more than 30 years of industry experience with large multinational companies,, including Bayer, Siemens and Ortho Clinical Diagnostics/QuidelOrtho, according to the announcement. At QuidelOrtho, he served as chief commercial officer and interim CEO, according to his LinkedIn profile.
In his new role, Iskra will focus on driving broader clinical use of the IsoPSA test.
Cleveland Diagnostics co-founder Arnon Chait, who has served as CEO, will remain with the company as chief innovation officer.
“This organizational alignment reflects the strength of both our validated diagnostic assets and the broader potential of our platform,” Chait said in a statement. “Given the value that our technology can provide across the diagnostics ecosystem, and now with experienced commercial-stage company leadership in place, we are well positioned to accelerate development of both our existing and next generation of tests.”
